Latest news and press releases about BGM Group Ltd. (BGM): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Operating from Chengdu, People's Republic of China, BGM Group Ltd. engages in the manufacturing and supply of active pharmaceutical ingredients (APIs), traditional Chinese medicine (TCM) derivatives, and various other related products across China.
Price
| Price | $9.35 |
| Market Cap | $119M |
| Exchange | NASDAQ |
| Country | CN |
Valuation Ratios
| Price / Book | 0.15 |
| EV / EBITDA | -9.61 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -5.37% |
| Return on Invested Capital | -2.80% |
| Return on Assets | -4.85% |
| Gross Margin | 12.81% |
| Operating Margin | -23.42% |
| Net Margin | -44.22% |
Related companies: ANIP · AVDL · CLOV · EWTX · GPCR · MESO · PAHC
Explore sector: Healthcare · Drug Manufacturers - Specialty & Generic
More sections of BGM: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Investment Academy — learn to analyze stocks